Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.

doi:10.1038/sj.tpj.6500157

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation.

The pharmacogenomics journal - 1 Jan 2003

Xie H-J, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A

Abstract excerpt

The role of polymorphic CYP2B6 in cyclophosphamide (CPA) bioactivation was investigated in human liver microsomes. A total of 67 human liver specimens were first genotyped with respect to the CYP2B6*5 and CYP2B6*6 variant alleles. CYP2B6 apoprotein levels in 55 liver microsomal preparations were assessed by immunoblotting. 4-Hydroxy-CPA and hydroxy-bupropion were quantified by using HPLC and LC-MS, respectively....

Topics

Analysis of Variance
Aryl Hydrocarbon Hydroxylases
Cyclophosphamide
Cytochrome P-450 CYP2B6
Genotype
Humans
Linear Models
Microsomes, Liver
Oxidoreductases, N-Demethylating
Polymorphism, Genetic

Source

Open in PubMed

Identifiers

PMID: 12629583
DOI: 10.1038/sj.tpj.6500157

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics